Global WholeHealth Partners Corp (OTC: GWHP) to Announce that Global is Now Offering All 4 Major Vaccines (AstraZeneca, J&J, Pfizer, Moderna) as Mentioned in 8k Filings 03/08/21, 06/09/21, 06/15/21, and 06/24/21
Global WholeHealth Partners Corp (OTC: GWHP) announced a collaboration with Nunzia Pharmaceutical to provide vaccines against COVID-19, specifically targeting the Delta variant, to governments at competitive prices. The vaccines have proven effective in minimizing infections and hospitalizations among the unvaccinated. The company is also preparing to launch Saliva Antibody IgG and IgM tests. GWHP has 56 FDA-approved products, including various COVID-19 tests, as they continue to expand their offerings amidst the ongoing pandemic, which has seen over 200 million global cases.
- Collaboration with Nunzia Pharmaceutical to provide COVID-19 vaccines to governments.
- Vaccines confirmed to be effective against the Delta variant.
- Introduction of new Saliva Antibody IgG and IgM tests.
- Offering 56 FDA-approved products, enhancing product portfolio.
- Dependence on government contracts may pose a risk if procurement slows.
- Competition from larger companies in the medical device industry may limit market share.
The Vaccines Have Been Verified to Assist in the Protection Against the Delta Variant
SAN CLEMENTE, CA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global WholeHealth Partners Corp (OTC:GWHP) continues the fight against COVID 19 by now offering the Vaccine directly to governments at the lowest prices available, through the agreement with Nunzia Pharmaceutical.
Current vaccines have shown effectiveness in protecting against or at least minimizing the damage from a delta infection, and the vast majority of infections and hospitalizations are among the unvaccinated.
The director-general of the World Health Organization called for a moratorium on coronavirus vaccine booster shots to allow vaccine access to countries struggling to obtain jabs as the global total of COVID-19 cases surpassed 200 million Wednesday.
WHO seeks moratorium on vaccine boosters; delta
Current vaccines have shown effectiveness in protecting against or at least minimizing the damage from a delta infection, and the vast majority of infections and hospitalizations are among the unvaccinated.
Call 714-609-91117 Michael Mitsunaga or Call 877-568-4947 to get your allocation or email Global at Sales@gwhpcorp.com
“Global understands that this is a war on COVID 19 and we are expanding our line of products to be able to fight,” states CEO Charles Storngo. “Our Saliva Antibody IgG and IgM are coming out soon to increase our fight.”
Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest lines of COVID 19 tests. Global’s WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer can detect all the current identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein, Global understands the need to be ahead of the virus to conquer the virus. Now, with the vaccine, Global is offering one of the largest lines of products to fight this virus.
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test Global has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases with an FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Currently, the Company offers 56 products FDA approved and many are Approved for OTC use, and 19 POC products approved by the FDA CLIA WAIVED.
Disclaimer:
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com
www.gwhpcorp.com
Forward-Looking Statements
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What recent agreement has Global WholeHealth Partners Corp (GWHP) made regarding COVID-19 vaccines?
How effective are the vaccines provided by GWHP against the Delta variant?
What new products is GWHP planning to launch?
How many FDA-approved products does GWHP currently offer?
What is the significance of the COVID-19 case milestone mentioned in the GWHP press release?
